Mabwell's 9MW2821 Becomes First Nectin-4 ADC to Enter Phase III Trial for Triple-Negative Breast Cancer

Key Takeaways

• 9MW2821 is the world’s first Nectin-4-targeting ADC to enter Phase III clinical trials for triple-negative breast cancer
• This marks Mabwell’s fourth pivotal trial for 9MW2821, demonstrating strong clinical development momentum
• The randomized Phase III study could lead to regulatory approval if successful, offering new hope for TNBC patients

---

Mabwell Advances Groundbreaking Cancer Treatment

Shanghai-based biopharmaceutical company Mabwell (688062.SH) announced on April 23, 2026, the initiation of a Phase III clinical study for its proprietary antibody-drug conjugate (ADC) 9MW2821, targeting Nectin-4 for triple-negative breast cancer (TNBC) treatment. This milestone positions 9MW2821 as the world’s first Nectin-4 ADC to reach Phase III testing for this aggressive cancer type.

Clinical Development Momentum

The Phase III trial represents Mabwell’s fourth pivotal study for 9MW2821, highlighting the company’s commitment to advancing this novel therapeutic approach. Triple-negative breast cancer, which accounts for approximately 15-20% of all breast cancers, is characterized by the absence of estrogen receptors, progesterone receptors, and HER2 protein, making it particularly challenging to treat with targeted therapies.

Nectin-4 as a Therapeutic Target

Nectin-4 is a cell adhesion molecule that is overexpressed in various solid tumors, including breast, bladder, and lung cancers. By targeting Nectin-4, ADCs like 9MW2821 can deliver cytotoxic payloads directly to cancer cells while minimizing damage to healthy tissue. This targeted approach represents a significant advancement in precision oncology.

Market Impact and Patient Implications

The advancement of 9MW2821 into Phase III trials addresses a critical unmet medical need in TNBC treatment. Current treatment options for TNBC patients are limited, with chemotherapy remaining the primary systemic therapy. If successful, 9MW2821 could provide a new targeted treatment option for patients with this aggressive form of breast cancer.

Mabwell’s integrated biopharmaceutical platform positions the company to potentially bring this innovative therapy from development through commercialization, representing a significant milestone for the Chinese biotech industry in oncology drug development.

---

Frequently Asked Questions

What makes 9MW2821 different from existing breast cancer treatments?

9MW2821 is an antibody-drug conjugate that specifically targets Nectin-4, a protein overexpressed in cancer cells. This allows for precise delivery of cancer-killing drugs directly to tumor cells while sparing healthy tissue, unlike traditional chemotherapy.

When could 9MW2821 become available to patients?

Phase III trials typically take 2-4 years to complete. If successful, regulatory review could add another 1-2 years, meaning 9MW2821 might potentially be available by 2029-2031, pending regulatory approval.

What is triple-negative breast cancer and why is it difficult to treat?

Triple-negative breast cancer lacks estrogen receptors, progesterone receptors, and HER2 protein, making it unresponsive to hormone therapies and HER2-targeted treatments. This limits treatment options primarily to chemotherapy, creating an urgent need for new targeted therapies.